MRK ▲ +0.1% - Merck & Co., Inc.
$MRK MERCK ENTERS INTO EXCLUSIVE GLOBAL LICENSE AGREEMENT WITH SCIBRUNCH THERAPEUTICS FOR SPR2015, AN INVESTIGATIONAL ORAL KRAS G12D (ON) INHIBITOR (DESIGNED TO BLOCK THE KRAS G12D GENE MUTATION THAT CAUSES TUMOURS TO GROW IN CANCERS LIKE PANCREATIC AND COLORECTAL CANCER)
28-SEP-2026 06:48 AM ET
Share this post
More filings for $MRK
MRK ▼ -0.4% - Merck & Co., Inc.Oct 13, 2026MRK ▲ +2.8% - Merck & Co., Inc.Oct 10, 2026MRK ▲ +0.3% - Merck & Co., Inc.Sep 30, 2026MRK ▲ +0.3% - Merck & Co., Inc.Sep 30, 2026MRK ▲ +0.4% - Merck & Co., Inc.Sep 25, 2026MRK ▲ +0.2% - Merck & Co., Inc.Sep 22, 2026
View full $MRK filing history →💬 Comments
Loading comments…
Leave a comment